Arnold & Porter Advises AstraZeneca in Research Collaboration with Silence Therapeutics
Arnold & Porter represented AstraZeneca in a research collaboration with Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases. The deal closed on March 24, 2020.
This multitarget collaboration will harness Silence's established siRNA platform to identify and progress liver-based targets and develop new delivery approaches for targeting other tissues such as the heart, lung and kidney. AstraZeneca may pursue development of up to 10 disease targets through the collaboration.
Partner Kristen Riemenschneider led the multidisciplinary Arnold & Porter transaction team, which also included partners Debbie Feinstein, Dr. Gottfried Freier and Sean Scanlon and associates Tyler Conway and Morgan Xu.